Expanded Access of Sotorasib

Non Small-cell Lung Cancer Clinical Trial

Official title:
A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation

Status No longer available

Clinical Trial Summary

The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advanced/unresectable/metastatic non small-cell lung cancer (NSCLC) with KRAS p.G12C mutation in a real-world setting.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Locally Advanced Metastatic NSCLC
Locally Advanced Unresectable NSCLC
Non Small-cell Lung Cancer

Clinical Trial Details

NCT number	NCT04667234
Study type	Expanded Access
Source	Amgen
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01652820` - Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer	Phase 2
Completed	`NCT01402089` - Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients	Phase 4
Completed	`NCT01257139` - Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments	Phase 3
Completed	`NCT01662635` - Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)
Active, not recruiting	`NCT05462795` - Liquid Biopsy for Early Non-small Lung Cancer Detection